Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $21.0600 (2.76%) ($19.9300 - $21.6700) on Mon. Nov. 9, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.12% (three month average) | RSI | 76 | Latest Price | $21.0600(2.76%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD advances 3.3% a day on average for past five trading days. | Weekly Trend | FOLD advances 7.3% a week on average for past two weeks. | Market Behavior | Rotation from growth to value for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(53%) IWO(50%) XBI(49%) IWM(46%) IWC(44%) | Factors Impacting FOLD price | FOLD will decline at least -1.56% in a week (0% probabilities). VIXM(-28%) VXX(-14%) UUP(-11%) UNG(-5%) IGOV(-2%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.56% (StdDev 3.12%) | Hourly BBV | 0.6 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $20.49(2.78%) | 10 Day Moving Average | $19.42(8.44%) | 20 Day Moving Average | $18.44(14.21%) | To recent high | -0.9% | To recent low | 63.6% | Market Cap | $5.438b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |